



## Clinical trial results:

### Use of 18F-PSMA-11 PET for detection of lesions in iodine refractory thyroid cancers

#### Summary

EudraCT number	2021-000456-19
Trial protocol	BE
Global end of trial date	18 July 2023

#### Results information

Result version number	v1 (current)
This version publication date	26 September 2024
First version publication date	26 September 2024
Summary attachment (see zip file)	Final Study Report (2021-000456-19_18F-PSMA-11-PET_Final_Study_Report.pdf)

#### Trial information

##### Trial identification

Sponsor protocol code	BC-09501
-----------------------	----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	University Hospital ghent
Sponsor organisation address	C. Heymanslaan 10, Gent, Belgium, 9000
Public contact	HIRUZ CTU, University Hospital Ghent, +32 93320500, hiruz.ctu@uzgent.be
Scientific contact	HIRUZ CTU, University Hospital Ghent, +32 93320500, hiruz.ctu@uzgent.be

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

Analysis stage	Final
Date of interim/final analysis	02 September 2024
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	18 July 2023
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

Main objective of the trial:

Demonstrate uptake of 18F-PSMA-11 in lesions in a radio-active iodine refractive thyroid carcinoma (RAI-RTC), either local recurrent disease, lymph nodes or distant metastasis.

Protection of trial subjects:

See attachment

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 September 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Belgium: 8
Worldwide total number of subjects	8
EEA total number of subjects	8

Notes:

---

**Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	8
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

See Final Study Report in attachment

### Pre-assignment

Screening details:

See Final Study Report in attachment

### Period 1

Period 1 title	Overall Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

See Final Study Report in attachment

### Arms

Arm title	Overall Trial
-----------	---------------

Arm description:

See Final Study Report in attachment

Arm type	Active comparator
Investigational medicinal product name	18F PSMA-11
Investigational medicinal product code	1940 IMP
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Infusion

Dosage and administration details:

See Final Study Report in attachment

Number of subjects in period 1	Overall Trial
Started	8
Completed	8

## Baseline characteristics

## End points

### End points reporting groups

Reporting group title	Overall Trial
Reporting group description: See Final Study Report in attachment	

### Primary: Demonstrate uptake of 18F-PSMA-11 in lesions

End point title	Demonstrate uptake of 18F-PSMA-11 in lesions <sup>[1]</sup>
End point description:	

End point type	Primary
End point timeframe: During the study	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: See Final Study Report in attachment

<b>End point values</b>	Overall Trial			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: See attachment				
number (not applicable)	8			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Secondary endpoints

End point title	Secondary endpoints
End point description:	

End point type	Secondary
End point timeframe: See Final Study Report in attachment	

<b>End point values</b>	Overall Trial			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: See Attachment				
number (not applicable)	8			

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

---

### Adverse events information<sup>[1]</sup>

---

Timeframe for reporting adverse events:

During the study

Assessment type	Systematic
-----------------	------------

---

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

---

Dictionary version	0
--------------------	---

---

Frequency threshold for reporting non-serious adverse events: 0 %

---

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: See Final Study Report in attachment

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported